<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01676259</url>
  </required_header>
  <id_info>
    <org_study_id>SLSG12D-P2</org_study_id>
    <nct_id>NCT01676259</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer</brief_title>
  <acronym>PROTACT</acronym>
  <official_title>A Prospective, Multinational, Multi-Center, Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy, Safety and Tolerability of siG12D-LODER in Combination With Standard of Care Chemotherapy in the Treatment of Patients With Locally Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Silenseed Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Silenseed Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this Phase II study a dose of 2.8 mg (eight 0.35 mg siG12D-LODERs) will be administered in&#xD;
      12-week cycles to patients with unresectable or borderline resectable locally advanced&#xD;
      pancreatic cancer combined with chemotherapy treatment.&#xD;
&#xD;
      Primary Outcome:&#xD;
&#xD;
      - ORR at 6 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this Phase II study a dose of 2.8 mg (eight 0.35 mg siG12D-LODERs) will be administered in&#xD;
      12-week cycles to patients with unresectable or borderline resectable LAPC combined with&#xD;
      chemotherapy treatment (Gemcitabine+nab-Paclitaxel or Folfirinox or modified Folfirinox).&#xD;
      This will be a study to assess the response rate of the siG12D-LODER in patients with&#xD;
      unresectable or borderline resectable LAPC. The study is of a single arm design with one arm&#xD;
      receiving siG12D-LODER + chemotherapy.&#xD;
&#xD;
      The investigational agent siG12D-LODER is a miniature biodegradable bio polymeric matrix that&#xD;
      encompasses the drug, designed and produced by Silenseed Ltd. The implantation of LODERs is&#xD;
      selected to meet current gastroenterology endoscopic ultrasound (EUS) biopsy procedures,&#xD;
      proved to be highly effective and safe.&#xD;
&#xD;
      siG12D-LODER has been studied in the escalating dose Phase I study of 15 patients, and&#xD;
      results showed high safety and tolerability profiles, with no single DLT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 7, 2018</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR at 6 months</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Pancreatic Ductal Adenocarcinoma</condition>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>siG12D-LODER + chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eight siG12D-LODER+Gemcitabine+nab-Paclitaxel or Eight siG12D-LODER+Folfirinox or Eight siG12D-LODER+modifide Folfirinox</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>siG12D-LODER</intervention_name>
    <description>The implantation of siG12D-LODERs is selected to meet current gastroenterology endoscopic ultrasound (EUS) biopsy procedures, proved to be highly effective and safe.</description>
    <arm_group_label>siG12D-LODER + chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine+nab-Paclitaxel</intervention_name>
    <description>Gemcitabine+nab-Paclitaxel</description>
    <arm_group_label>siG12D-LODER + chemotherapy</arm_group_label>
    <other_name>Chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folfirinox</intervention_name>
    <description>Folfirinox or modified Folfirinox</description>
    <arm_group_label>siG12D-LODER + chemotherapy</arm_group_label>
    <other_name>Chemotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Age&#xD;
&#xD;
        1. Subject must be 18 years of age or older at the time of signing the informed consent.&#xD;
&#xD;
        Type of Subject and Disease Characteristics&#xD;
&#xD;
          1. Histologically or cytologically confirmed adenocarcinoma of the pancreas.&#xD;
&#xD;
          2. Locally advanced pancreatic cancer stage III according to The American Joint Committee&#xD;
             on Cancer (AJCC) and defined as T4, N (any) and M0, according to the three factors, T&#xD;
             (tumor), N (node involvement), and M (metastases), of the National Comprehensive&#xD;
             Cancer Network TNM classification.&#xD;
&#xD;
          3. Allocated to receive one of the following chemotherapies: gemcitabine plus&#xD;
             nab-paclitaxel, FOLFIRINOX or modified FOLFIRIONOX as first line treatment for&#xD;
             pancreatic cancer.&#xD;
&#xD;
          4. Have a target tumor that is accessible for intratumoral administration by EUS as&#xD;
             determined by the radiologist/gastroenterologist performing the EUS intratumoral&#xD;
             administration, according to The American Society for Gastrointestinal Endoscopy&#xD;
             (ASGE) guidelines (https://www.asge.org/home/practice-support/guidelines).&#xD;
&#xD;
          5. Have measurable disease. Subject will have a histologically-confirmed disease and must&#xD;
             have clinically and/or radiographically documented measurable primary disease&#xD;
             according to RECIST v1.1. At least one site of disease must be unidimensionally&#xD;
             measurable.&#xD;
&#xD;
             Diagnostic Assessments&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) Performance Scale of ≤ 1.&#xD;
&#xD;
          7. Demonstrate adequate organ function as defined below:&#xD;
&#xD;
               -  serum creatinine &lt;1.6 mg/dL&#xD;
&#xD;
               -  international normalized ratio (INR) &lt; 1.5 U&#xD;
&#xD;
               -  absolute neutrophil count (ANC) &gt; 1.5 x 109/L&#xD;
&#xD;
               -  platelets ≥ 100 x 109/L&#xD;
&#xD;
               -  hemoglobin ≥ 9 mg/dL&#xD;
&#xD;
               -  alanine transaminase (ALT) and aspartate aminotransferase (AST) ≤ 5 times upper&#xD;
                  limit of normal (ULN)&#xD;
&#xD;
               -  bilirubin ≤ 1.5 x ULN Sex&#xD;
&#xD;
          8. Male and/or female. Contraceptive use by men or women should be consistent with local&#xD;
             regulations regarding the methods of contraception for those participating in clinical&#xD;
             studies.&#xD;
&#xD;
          9. Women of childbearing potential (WOCBP): a negative serum or urine pregnancy test&#xD;
             during screening.&#xD;
&#xD;
         10. Subject of childbearing potential, if sexually active (both men and women) must agree&#xD;
             to use a barrier method of contraception, from the time of administration of the first&#xD;
             treatment and for at least 8 weeks after EOT visit day.&#xD;
&#xD;
             Informed Consent&#xD;
&#xD;
         11. Capable of giving signed informed consent which includes compliance with the&#xD;
             requirements and restrictions listed in the informed consent form (ICF) and in this&#xD;
             protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects are excluded from the study if any of the following criteria apply:&#xD;
&#xD;
        Medical Conditions&#xD;
&#xD;
          1. Subjects with resectable pancreatic cancer.&#xD;
&#xD;
          2. Evidence of metastatic disease.&#xD;
&#xD;
          3. Other malignancy that would interfere with the current intervention.&#xD;
&#xD;
          4. Any evidence of ascites (beyond trace).&#xD;
&#xD;
          5. Bulky celiac adenopathy (≥2.5 cm) or non-adenocarcinoma histology.&#xD;
&#xD;
          6. Previously treated malignancies, except for adequately treated non-melanoma skin&#xD;
             cancer, in situ cancer, or other cancers from which the subject has been disease-free&#xD;
             for at least 2 years.&#xD;
&#xD;
          7. History of clinically significant coagulopathy.&#xD;
&#xD;
          8. Major surgery, other than diagnostic surgery, within 4 weeks prior to study entry&#xD;
             without complete recovery.&#xD;
&#xD;
          9. New York Heart Association (NYHA) Class III or IV, cardiac disease, myocardial&#xD;
             infarction within 4 months prior to the first chemotherapy cycle Day 1, unstable&#xD;
             arrhythmia or symptomatic peripheral arterial vascular disease.&#xD;
&#xD;
         10. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic&#xD;
             therapy.&#xD;
&#xD;
         11. Known active infection with human immunodeficiency virus (HIV), hepatitis B virus, or&#xD;
             hepatitis C virus.&#xD;
&#xD;
         12. Females who are pregnant or breast-feeding.&#xD;
&#xD;
         13. Concomitant disease or condition that could interfere with the conduct of the study,&#xD;
             or that would, in the opinion of the Investigator, pose an unacceptable risk to the&#xD;
             subject in this study.&#xD;
&#xD;
             Prior/Concomitant Therapy&#xD;
&#xD;
         14. Any prior therapy for the treatment of pancreatic malignancy (including chemotherapy,&#xD;
             immunotherapy, vaccines, monoclonal antibodies, major surgery, or irradiation, whether&#xD;
             conventional or investigational).&#xD;
&#xD;
         15. Prior therapy with any hypoxic cytotoxic agent (hypoxia-targeting drugs).&#xD;
             Prior/Concurrent Clinical Study Experience&#xD;
&#xD;
         16. Subjects who are participating or participated in an investigational drug or device&#xD;
             study (within 28 days prior to study entry from the last study dose date).&#xD;
&#xD;
             Other Exclusions:&#xD;
&#xD;
         17. Unwillingness or inability to comply with the study protocol for any reason.&#xD;
&#xD;
         18. Known allergy to sesame oil.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eileen M O'Reilly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Talia Golan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheba Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Orit Pollack-Shragai, MSc, MBA</last_name>
    <phone>+972-52-8466267</phone>
    <email>orit@silenseed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hackensack Meridian Health</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Celina Ang, MD</last_name>
      <phone>212-824-8551</phone>
      <email>celina.ang@mssm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Christopher DiMaio, MD</last_name>
      <phone>212-241-7531</phone>
      <email>christopher.dimaio@mountsinai.org</email>
    </contact_backup>
    <investigator>
      <last_name>Celina Ang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christopher J DiMaio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eileen M O'Reilly, MD</last_name>
      <phone>646-888-4182</phone>
      <email>oreillye@mskcc.org</email>
    </contact>
    <contact_backup>
      <last_name>Anna M Varghese, MD</last_name>
      <phone>646-888-4308</phone>
      <email>VarghesA@mskcc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Eileen M. O'Reilly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna M Varghese, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark A Schattner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milind Javle, MD</last_name>
      <phone>713-792-5434</phone>
      <email>mjavle@mdanderson.org</email>
    </contact>
    <contact_backup>
      <last_name>Manoop Bhutani, MD</last_name>
      <phone>1-713-792-2121</phone>
      <email>Manoop.Bhutani@mdanderson.org</email>
    </contact_backup>
    <investigator>
      <last_name>Milind Javle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manoop Bhutani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>3525408</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerya Semenysty, MD</last_name>
      <phone>+972-4-7776419</phone>
      <email>semenysty@rambam.health.gov.il</email>
    </contact>
    <contact_backup>
      <last_name>Iyad Khamaysi, MD</last_name>
      <phone>+972-4-7773626</phone>
      <email>z_khamaysi@rambam.health.gov.ill</email>
    </contact_backup>
    <investigator>
      <last_name>Valerya Semenysty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Iyad Khamaysi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49102</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center (Tel H'shomer)</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Talia Golan, MD</last_name>
      <phone>+972-3-5305338</phone>
      <email>Talia.Golan@sheba.health.gov.il</email>
    </contact>
    <contact_backup>
      <last_name>Maor Lahav, MD</last_name>
      <phone>+972- 3-5305875</phone>
      <email>Maor.Lahav@sheba.health.gov.il</email>
    </contact_backup>
    <investigator>
      <last_name>Talia Golan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maor Lahav, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sourasky MC (Ichilov) Tel Aviv Israel</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ravit Geva, M.D</last_name>
      <phone>972- 36973082</phone>
      <email>ravitg@tlvmc.gov.il</email>
    </contact>
    <contact_backup>
      <last_name>Adam Phillips, M.D</last_name>
      <email>adamp@tlvmc.gov.il</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Assaf Harofeh Medical Center</name>
      <address>
        <city>Tzrifin</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.silenseed.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 28, 2012</study_first_submitted>
  <study_first_submitted_qc>August 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2012</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>siRNA</keyword>
  <keyword>RNA interference (RNAi)</keyword>
  <keyword>Cancer</keyword>
  <keyword>Pancreatic ductal adenocarcinoma</keyword>
  <keyword>Locally Advanced Pancreatic cancer</keyword>
  <keyword>Solid tumor</keyword>
  <keyword>Non operable pancreatic ductal adenocarcinoma</keyword>
  <keyword>Borderline resectable</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Folfirinox</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

